| ||||||
| 221 West Grand Avenue, Suite 200, Montvale, NJ, 07645, US. TEL: 201-934-5000 http://www.alteon.com | ||||||
| Last Sale | Net Change | % Change | Volume | Last Updated | ||
|---|---|---|---|---|---|---|
| N.A. | N.A. | N.A. | N.A. | 11/20/09 4:00 PM ET | ||
| ||||||||||||||||||||||
 |
|
||||||||||||||||||||||
| ||||
| Security Type | Common Stock | Specialist | 958 | |
| Industry | Health Services, Pharmaceuticals, and Medical Diagnostics | Trading Post | 07 | |
| Primary Exchange | Amex | SEC Filings | ||
| ||||
| Description |
|
Alteon, Inc., a product-based biopharmaceutical company, engages in the research, discovery, and development of small molecule drugs to treat and prevent cardiovascular disease and diabetes. The company, together with its subsidiary, develops ALT-2074, a Phase II clinical development product, which is a glutathione peroxidase mimetic for reducing the morbidity and mortality of patients with diabetes following a myocardial infaraction; and Alagebrium chloride or alagebrium, also a Phase II clinical development product, which is an advanced glycation end-product crosslink breaker for diastolic heart failure. It also owns a license to a proprietary genetic biomarker that has shown the potential to identify patients responsive to ALT-2074. The company was founded in 1986 and is headquartered in Montvale, New Jersey. |
| Quote |
| ||||
| Last Sale | N.A. (N.A.) | |||
| Net Change | N.A. | |||
| % Change | N.A. | |||
| Previous Close | N.A. | |||
| Today’s Open | N.A. | |||
| Today’s High | N.A. | |||
| Today’s Low | N.A. | |||
| Volume | N.A. | |||
| 52 Week High | N.A. | |||
| 52 Week Low | N.A. | |||
| ||||
| Chart |
| 3mo | 6mo | 12mo | 24mo | 36mo | 48mo | 60mo |
|
| Click here to view the data behind the chart. |
| Fundamentals |
|
||||
| P/E ratio | N.A. | Short Interest | N.A. | |
| Earnings Per Share | N.A. | Current yield | N.A. | |
| Shares Outstanding | N.A. | Dividend Info | ||
| Market Cap | N.A. | |||
|
||||
|
|
